Prognostic significance of C-reactive protein in patients with intermediate-risk metastatic renal cell carcinoma treated with molecular targeted therapy

By                            

Oncology Letters, Vol. 8, Iss. 2, 2014-01 ,pp. : 881-885

Spandidos Publications

Access to resources Recommend Favorite

Association of high cost sharing and targeted therapy initiation among elderly Medicare patients with metastatic renal cell carcinoma

By  

Cancer Medicine, Vol. 7, Iss. 1, 2018-01 ,pp. : 75-86

John Wiley & Sons Inc

Access to resources Recommend Favorite

Predicting outcome to VEGF-targeted therapy in metastatic clear-cell renal cell carcinoma: data from recent studies

By Golshayan Ali-Reza   Brick Ashley J   Choueiri Toni K  

Future Oncology, Vol. 4, Iss. 1, 2008-02 ,pp. : 85-92

Future Medicine

Access to resources Recommend Favorite

An early phase II trial of S-1 in Japanese patients with cytokine-refractory metastatic renal cell carcinoma

By Naito Seiji   Tsukamoto Taiji   Usami Michiyuki   Fujimoto Hiroyuki   Akaza Hideyuki  

Cancer Chemotherapy and Pharmacology, Vol. 66, Iss. 6, 2010-11 ,pp. : 1065-1070

Springer Publishing Company

Access to resources Recommend Favorite

Prognostic outcome in patients treated with tyrosine kinase inhibitors as first-line molecular-targeted therapy for metastatic renal cell carcinoma: Experience in real-world clinical practice in Japan

By          

Molecular and Clinical Oncology, Vol. 3, Iss. 3, 2015-01 ,pp. : 601-606

Science Publishers

Access to resources Recommend Favorite